Nucleic acid releasing agent suitable for rapid release of multiple samples and nucleic acid releasing method
By using nucleic acid release agents composed of specific concentrations, the problems of inconvenient transportation, complex operation and high cost of nucleic acid extraction methods in the prior art are solved, and rapid and highly compatible nucleic acid release and preservation are achieved. It is suitable for a variety of samples and is suitable for use in many samples. Downstream experiments in PCR and other aspects.
Patent Information
- Application Number
- CN202411283870.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-13
- Publication Date
- 2024-11-26
AI Technical Summary
The existing nucleic acid extraction methods have problems such as inconvenient transportation, complex operation steps, labor-intensive, high cost, inability to compatible with multiple samples, long release time, and inhibitors, which limit the application and promotion of nucleic acid release agents.
Guanidine isothiocyanate at a concentration of 10mM-50mM, ammonium sulfate at a concentration of 20mM-200mM, metal ion chelating agent at a concentration of 1mM-5mM, buffer solution at a concentration of 50mM-500mM, and non-ionic detergent at a concentration of 0.1%-10% , a nucleic acid release agent composed of 0.05%-1% anionic active agent and 0.05%-5% PCR enhancer, combined with appropriate pH and temperature, achieve rapid release and storage.
It realizes rapid cracking of cells within 1-3 minutes at room temperature, shortens sample extraction time, provides protection as sample preservation solution, is compatible with multiple samples, is suitable for downstream experiments such as PCR, and does not require additional resolvent, which improves detection efficiency and safety. .
Smart Images

Figure CN119020459A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of nucleic acid detection, and in particular to a nucleic acid releasing agent and a nucleic acid releasing method suitable for rapid release of multiple samples. Background Art
[0002] Real-time fluorescence quantitative PCR technology is an advanced technology that can quantitatively detect nucleic acids. Its principle is to monitor the amplification process of nucleic acids by collecting fluorescent signals in real time, thereby achieving quantitative detection of unknown samples. It has been widely used. Before PCR amplification, it is necessary to extract and purify the nucleic acid of the unknown sample. This step is crucial for subsequent PCR amplification.
[0003] At present, the commonly used methods for nucleic acid extraction are as follows: (1) Boiling method: adding lysis buffer to the sample, lysing it at high temperature and then centrifuging to obtain nucleic acids; (2) Centrifugal column method: using silica gel membrane or glass fiber membrane for adsorption, purification and elution to obtain nucleic acids; (3) Magnetic bead method: using lysis buffer to lyse cells at room temperature or high temperature, and then using magnetic beads to adsorb, purify and elute nucleic acids; (4) Nucleic acid release agent technology: using alkaline solutions, surfactants or chemical reagents such as guanidine salts in the release agent to directly lyse the sample and obtain nucleic acids.
[0004] Nucleic acid extraction technology is the basis for subsequent nucleic acid testing, research or product development. Rapid and simple nucleic acid extraction technology can significantly improve detection efficiency and accuracy. For the above-mentioned traditional nucleic acid extraction methods, such as boiling method, centrifugal column method and magnetic bead method, there are generally some disadvantages: (1) inconvenient transportation, it is inconvenient to transport with ethanol or isopropanol, and it is flammable and explosive; (2) the manual method has complicated operation steps. The operation steps of these methods are relatively cumbersome, time-consuming and labor-intensive. (3) Both the centrifugal column method and the magnetic bead method require multiple steps such as nucleic acid adsorption, washing and elution. The supporting instruments are expensive to use. For example, the boiling method and the centrifugal column method both require a supporting centrifuge for use, and the magnetic bead method requires a nucleic acid extractor; (4) The membrane method and the magnetic bead method have high costs such as centrifugal column membranes and magnetic beads, which will have a great impact on the application of certain low-end fields of the entire product.
[0005] The current nucleic acid release agent technology has the following technical problems: (1) limited applicability, incompatible with a variety of samples, and cannot be used as a transport preservation solution; (2) some release agents need to be heated during nucleic acid extraction, which not only prolongs the operation time and easily causes aerosol pollution, but also requires heating equipment; (3) the release time of most release agents is too long, mostly more than 5 minutes; (4) the cost is relatively expensive, and the price of some components is high, which will inevitably hinder the large-scale promotion and application of nucleic acid release agents. (5) Most release agents have certain inhibitors and cannot be used to freeze-dry the entire sample. When the sample volume exceeds 40%, the subsequent PCR amplification will be completely inhibited; (6) It cannot be used as a sample preservation solution to preserve samples; (7) The main components of the release agent will have an inhibitory effect on downstream PCR experiments, which limits the amount of sample addition and requires a compatible amplification system with tolerance.
[0006] In this regard, the inventor of this patent combined his experience, thought about the problems encountered in his work, read a large amount of scientific research materials and literature, and conducted searches and novelties to gradually conceive and design this application to solve related technical problems. Summary of the invention
[0007] The present invention aims to solve one of the technical problems in the related art at least to a certain extent. To this end, the purpose of the present invention is to provide a nucleic acid release agent and a nucleic acid release method suitable for rapid release of multiple samples.
[0008] To achieve one of the above purposes, a nucleic acid releaser suitable for rapid release of multiple samples according to an embodiment of the present invention includes guanidine thiocyanate at a concentration of 10mM-50mM, ammonium sulfate at a concentration of 20mM-200mM, a metal ion chelator at a concentration of 1mM-5mM, a buffer solution at a concentration of 50mM-500mM, a non-ionic detergent with a volume percentage of 0.1%-10%, an anionic active agent with a volume percentage of 0.05%-1%, and a PCR enhancer with a volume percentage of 0.05%-5%.
[0009] In addition, the nucleic acid release agent and nucleic acid release method suitable for rapid release of multiple samples according to the above embodiments of the present invention may also have the following additional technical features:
[0010] According to one embodiment of the present invention, the concentration of guanidine isothiocyanate is 20mM-40mM.
[0011] According to one embodiment of the present invention, the concentration of ammonium sulfate is 50mM-150mM.
[0012] According to one embodiment of the present invention, the metal ion chelator is ethylenediaminetetraacetic acid (EDTA) with a concentration of 1 mM-3 mM.
[0013] According to one embodiment of the present invention, the buffer is Tris-HCl buffer with a concentration of 100 mM-250 mM.
[0014] According to one embodiment of the present invention, the non-ionic detergent comprises Triton X-100, Tween 20 and ethylphenyl polyethylene glycol (NP-40), and the volume percentage thereof is 0.1%-5%.
[0015] According to an embodiment of the present invention, the anionic surfactant comprises sodium dodecyl sulfate (SDS) and sodium lauroyl sarcosinate (SLS), and the volume percentage thereof is 0.1%-0.5%.
[0016] According to one embodiment of the present invention, the PCR enhancer comprises one or more of trehalose, betaine, bovine serum albumin, glycine, gelatin, glycine and formamide, and the volume percentage thereof is 0.1%-1%.
[0017] To achieve the second objective, according to the nucleic acid release method of an embodiment of the present invention, the nucleic acid release agent as described above is used to perform PCR detection of nucleic acid, and the pH value of the nucleic acid release agent is 7.5-8.5.
[0018] According to one embodiment of the present invention, the volume ratio of the nucleic acid releaser to the nucleic acid sample is 1:(1-10), the operating temperature of the nucleic acid releaser is 10°C-30°C, and the release time of the nucleic acid releaser is 1min-3min.
[0019] The beneficial effects of the present invention are:
[0020] First, the nucleic acid releaser of the present invention has a protein structure that can quickly crack cells, viruses, etc., and can complete sample release within 1-3 minutes at room temperature, greatly shortening the sample extraction time and saving a lot of time for subsequent rapid testing.
[0021] Second, the nucleic acid releaser of the present invention can be used as a sample preservation liquid to provide protection for bacteria and viruses in the oral cavity, blood, and cervical exfoliated cells, and prevent degradation by DNase and RNase enzymes. There is no significant degradation of nucleic acid samples stored and transported for more than 2 days at room temperature.
[0022] Thirdly, the present invention contains various active agents and strong protein denaturants, which can quickly inactivate viruses and other pathogenic microorganisms in samples and has high safety.
[0023] Fourthly, the nucleic acid release method of the present invention is compatible with multiple samples and can quickly release nucleic acids from serum, plasma, oral swabs, and cervical exfoliated cell samples. The released nucleic acids can be used for downstream experiments such as PCR, cloning, sequence analysis, and molecular hybridization.
[0024] Fifthly, the nucleic acid releaser of the present invention can be used as a resolubilizing agent in a freeze-dried reagent without adding an additional resolubilizing agent or water, and the addition of the whole sample has no significant inhibitory effect on the freeze-dried reagent.
[0025] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the structures shown in these drawings without paying creative work.
[0027] Figure 1 This is a graph showing the comparison of the results of extracting the novel coronavirus (COVID-19) from oral samples using different release agent formulas 1-9 and a comparative reagent in Example 1;
[0028] Figure 2 This is a graph showing the comparison of the results of extracting HBV samples with different release agent formulations 1-6 and a control reagent in Example 2;
[0029] Figure 3 This is a graph showing the comparison of the results of extracting HPV samples using different release agent formulations 1-6 and a control group reagent in Example 3;
[0030] The realization of the purpose, functional features and advantages of the present invention will be further explained in conjunction with embodiments and with reference to the accompanying drawings. DETAILED DESCRIPTION
[0031] The embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the drawings of the specification, wherein the same or similar reference numerals throughout represent the same or similar elements or elements with the same or similar functions. The embodiments described below with reference to the drawings are exemplary and are intended to be used to explain the present invention, but cannot be understood as limiting the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in the field without creative work are within the scope of protection of the present invention.
[0032] In the description of the present invention, it is to be understood that the terms “center”, “longitudinal”, “lateral”, “length”, “width”, “thickness”, “up”, “down”, “front”, “back”, “left”, “right”, “vertical”, “horizontal”, “top”, “bottom”, “inside”, “outside”, “clockwise”, “counterclockwise”, “axial”, “circumferential”, “radial”, etc., indicating orientations or positional relationships are based on the orientations or positional relationships shown in the drawings of the specification, and are only for the convenience of describing the present invention and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore should not be understood as limiting the present invention.
[0033] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. In the description of the present invention, the meaning of "plurality" is two or more, unless otherwise clearly and specifically defined.
[0034] In the present invention, unless otherwise clearly specified and limited, the terms "installed", "connected", "connected", "fixed" and the like should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or it can be an indirect connection through an intermediate medium, or it can be the internal communication of two components. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.
[0035] In the present invention, unless otherwise clearly specified and limited, a first feature being "above" or "below" a second feature may include that the first and second features are in direct contact, or may include that the first and second features are not in direct contact but are in contact through another feature between them. Moreover, a first feature being "above", "above" and "above" a second feature includes that the first feature is directly above and obliquely above the second feature, or simply indicates that the first feature is higher in level than the second feature. A first feature being "below", "below" and "below" a second feature includes that the first feature is directly below and obliquely below the second feature, or simply indicates that the first feature is lower in level than the second feature.
[0036] The nucleic acid releasing agent and nucleic acid releasing method suitable for rapid release of multiple samples according to embodiments of the present invention are described in detail below with reference to the accompanying drawings.
[0037] According to an embodiment of the present invention, a nucleic acid releaser suitable for rapid release of multiple samples includes guanidine thiocyanate at a concentration of 10mM-50mM, ammonium sulfate at a concentration of 20mM-200mM, a metal ion chelator at a concentration of 1mM-5mM, a buffer solution at a concentration of 50mM-500mM, a non-ionic detergent with a volume percentage of 0.1%-10%, an anionic active agent with a volume percentage of 0.05%-1%, and a PCR enhancer with a volume percentage of 0.05%-5%.
[0038] Based on the above, it is clear that, in specific implementation, the present application is mainly used as a nucleic acid release agent suitable for rapid release of multiple samples.
[0039] Specifically, when applying the present application, the present application is configured according to the above-mentioned components and proportions, and the present application can be used to extract nucleic acid samples to realize PCR detection.
[0040] The guanidine isothiocyanate contained in the nucleic acid releaser of the present application is an organic compound with a molecular formula of C2H6N4S, which is used for denaturing and lysing cells and extracting RNA and DNA. It has no RNase and DNase activity, can quickly break cells and inhibit nucleases released by cells.
[0041] The ammonium sulfate contained in the nucleic acid releaser described in the present application is an inert substance and is not easy to react with other biologically active substances. It can protect the protein activity to the greatest extent during the purification process.
[0042] The metal ion chelator contained in the nucleic acid release agent of the present application is a compound that can form a stable complex with a metal ion. These compounds usually contain multiple coordination sites and can surround the metal ion to form a ring structure. This effect is called chelation. After the chelator binds to the metal ion, it will change the chemical properties of the metal ion, making it inactive or easier to remove.
[0043] The buffer contained in the nucleic acid releaser described in the present application has a certain function of keeping the pH value of the solution basically unchanged. For example, when a certain amount of acid and alkali are added to certain solutions, it has the effect of hindering the change of the pH of the solution, which is called buffering effect. Such a solution is called a buffer.
[0044] The nonionic detergent contained in the nucleic acid releaser described in the present application is an amphiphilic small molecule that can form microcapsules in water. Such microcapsules can interact with the lipid bilayer to form microcapsules of a mixture of phospholipids and detergents, or microcapsules of a mixture of proteins, detergents and phospholipids. They exist in the aqueous solution in the form of a phospholipid-detergent-protein or a detergent-protein mixture.
[0045] The anionic active agent contained in the nucleic acid releasing agent described in the present application is a type of surfactant and has good cleaning, foaming, dispersing, emulsifying, wetting and other properties.
[0046] The PCR enhancer contained in the nucleic acid releaser described in the present application can play a certain protective role on the enzyme and can also enhance the sensitivity of PCR, and the polar organic solvent can enhance the solubility performance.
[0047] Furthermore, in a specific implementation, according to one embodiment of the present invention, the concentration of the guanidine isothiocyanate is preferably 20 mM-40 mM.
[0048] Furthermore, in a specific implementation, according to one embodiment of the present invention, the concentration of ammonium sulfate is preferably 50mM-150mM, more preferably 100mM-150mM;
[0049] Furthermore, in the technical solution, according to an embodiment of the present invention, the metal ion chelator is ethylenediaminetetraacetic acid (EDTA), and its concentration is preferably 1 mM-3 mM.
[0050] And in the technical solution, according to one embodiment of the present invention, the buffer is Tris-HCl buffer, and its concentration is preferably 100mM-250mM.
[0051] In addition, in a specific implementation, according to one embodiment of the present invention, the non-ionic detergent comprises Triton X-100, Tween 20 and ethylphenyl polyethylene glycol (NP-40), and the volume percentage thereof is preferably 0.1%-5%, more preferably 0.5%-1%;
[0052] Furthermore, in a specific implementation, according to an embodiment of the present invention, the anionic surfactant comprises sodium dodecyl sulfate (SDS) and sodium lauroyl sarcosinate (SLS), and the volume percentage thereof is preferably 0.1%-0.5%.
[0053] Again, in a specific implementation, according to an embodiment of the present invention, the PCR enhancer comprises one or more of trehalose, betaine, bovine serum albumin, glycine, gelatin, glycine and formamide, and the volume percentage thereof is 0.1%-1%. The PCR enhancer preferably comprises trehalose, betaine and formamide;
[0054] Meanwhile, according to the nucleic acid release method of an embodiment of the present invention, it mainly uses the nucleic acid release agent as described above to perform PCR detection of nucleic acid, and the pH value of the nucleic acid release agent is preferably 7.5-8.5.
[0055] Furthermore, in a specific implementation, according to one embodiment of the present invention, the volume ratio of the nucleic acid releasing agent to the nucleic acid sample is 1:(1-10), such as 1:1.0, 1:2.0, 1:3.0, 1:4.0, 1:5.0, 1:6.0, 1:7.0, 1:8.0, 1:9.0 or 1:10.0;
[0056] And in a specific implementation, the operating temperature of the nucleic acid releaser is 10°C-30°C, such as 10°C, 15°C, 20°C, 25°C or 30°C;
[0057] The release time of the nucleic acid releaser is 1 min-3 min, for example 1 min, 2 min or 3 min.
[0058] The following describes in detail the implementation cases of the nucleic acid releasing agent provided in the embodiments of the present invention when used.
[0059] Example 1: Applying the present application to the extraction of nucleic acid from oropharyngeal swab samples;
[0060] 1) Prepare a batch of nucleic acid releasing agents provided by the embodiments of the present invention according to the formula shown in Table 1 for standby use.
[0061] Table 1: Composition of different nucleic acid releaser components
[0062]
[0063] 2) The experimental process is as follows: The extraction reagent uses the "Nucleic Acid Releaser Kit" produced by Dexia. The detection kit uses the Dexia Biotech COVID-19 Nucleic Acid Detection Kit. The sample uses the purchased Bondeson Enterprise reference product and is mixed with the negative oral sample in proportion. The competitor's kit uses a certified magnetic bead kit from a Guangzhou company.
[0064] 3) The extraction process is as follows: For oral swab samples, directly insert the swab into the nucleic acid releaser (3ml tube) or insert the swab head into the preservation solution, add the preservation solution to the nucleic acid releaser (200μL) in a 1:1 ratio, manually shake the nucleic acid releaser 15 times after adding the sample, and let it stand at room temperature for 2 minutes; add it to the PCR reaction reagent for amplification; the comparison procedure of the competitive magnetic bead extraction reagent is shown in Table 2 below (the sample is 200μL);
[0065] Table 2: Comparison of reagent extraction reagents Fully automatic extraction process
[0066]
[0067] 4) After the extraction of reagents is completed, detection and comparison are performed. The specific detection reaction system is shown in Table 3 below;
[0068] Table 3: PCR reaction system
[0069]
[0070] Amplification Procedure:
[0071]
[0072] The reaction solution was divided into 8 tubes according to the reaction system, and then the extracted nucleic acid was added. The lid was closed, centrifuged instantly, the bubbles were removed, and the PCR was performed on the machine. The CT values of the novel coronavirus (COVID-19) samples extracted with different formulas were amplified as shown in Table 4 below.
[0073] Table 4: CT values of novel coronavirus (COVID-19) samples extracted with different formulas
[0074]
[0075]
[0076] From the results in Table 4 above, it can be seen that the best effects are formulas 1, 2, and 3, which are better than reagents of other formulas and comparable to the magnetic bead comparison reagents. The entire release time is completed within 3 minutes, and there is no obvious inhibition on downstream PCR detection.
[0077] For relevant results, please refer to the attached Figure 1 shown.
[0078] Example 2: Applying the present application to the release of HBV viral nucleic acid from a blood sample;
[0079] 1) Prepare a batch of reagents according to the formula shown in Table 5 for standby use.
[0080] Table 5: Composition of different release agent components used
[0081]
[0082] 2) The experimental process is as follows: The extraction reagent uses the "Nucleic Acid Releaser Kit" produced by Dexia Company. The detection kit uses the Dexia Bio HBV Virus Nucleic Acid Detection Kit. The sample uses a hepatitis B positive sample from a hospital in Shenzhen. The competitor's kit uses a certified magnetic bead alcohol kit from a company in Guangzhou.
[0083] 3) The extraction process is as follows: add blood to the release agent (100 μL) at a ratio of 1:1, shake the release agent 15 times manually, and let it stand at room temperature for 3 minutes; add it to the PCR reaction reagent for amplification; the comparison procedure of the competitive magnetic bead extraction reagent is shown in Table 6 below (the sample is 200 μL);
[0084] Table 6: Comparative reagent extraction reagent fully automatic extraction process
[0085]
[0086]
[0087] 4) After the extraction of reagents is completed, detection and comparison are performed. The specific detection reaction system is shown in Table 7 below;
[0088] Table 7: PCR reaction system
[0089]
[0090] Amplification Procedure:
[0091]
[0092] The reaction solution was divided into 8 tubes according to the reaction system, and then the extracted nucleic acid was added. The lid was closed, centrifuged instantly, the bubbles were removed, and the PCR was performed on the machine. The CT values of HBV amplification extracted with different formulas were shown in the following Table 8.
[0093] Table 8: CT values of HBV amplification extracted by different formulas
[0094]
[0095]
[0096] From the results in Table 8 above, it can be seen that the best effect is formula 1, which is better than the reagents of other formulas and the control magnetic bead reagent. The entire release time is completed within 4 minutes, and there is no obvious inhibition on the downstream PCR detection.
[0097] For relevant results, please refer to the attached Figure 2 shown.
[0098] Example 3: Applying the present application to the release of HPV nucleic acid from cervical exfoliated cells;
[0099] 1) Prepare a batch of reagents according to the formula shown in Table 9 for standby use.
[0100] Table 9: Composition of different release agent components used
[0101]
[0102] 2) The experimental process is as follows: The extraction reagent uses the "Nucleic Acid Releaser Kit" produced by Dexia Company. The detection kit uses the Dexia Bio Human Papillomavirus Nucleic Acid Detection Kit. The sample uses Shenzhen Jingliang Human Papillomavirus (HPV Cell) Monotyping Quality Control Product - Human Papillomavirus (HPV16) Cell Quality Control Product (Product No. GW-IPF030, concentration 1x105copies / mL), and the cell sample is diluted to an appropriate concentration. The competitor's kit uses a certified magnetic bead alcohol kit from a company in Guangzhou.
[0103] 3) The extraction process is as follows: add the cell quality control product to the release agent (100 μL) at a ratio of 1:1, shake the release agent manually left and right 15 times, and let it stand at room temperature for 3 minutes; add it to the PCR reaction reagent for amplification; the comparison procedure of the competitive magnetic bead extraction reagent is shown in Table 10 below (sample 200 μL);
[0104] Table 10: Comparative reagent extraction reagent fully automatic extraction process
[0105]
[0106] 4) After the extraction of reagents is completed, detection and comparison are performed. The specific detection reaction system is shown in Table 11 below;
[0107] Table 11: PCR reaction system
[0108]
[0109] Amplification Procedure:
[0110]
[0111] The reaction solution was divided into 8 tubes according to the reaction system, and then the extracted nucleic acid was added. The lid was closed, centrifuged instantly, the bubbles were removed, and the PCR was performed on the machine. The CT values of HPV samples extracted with different formulas were amplified as shown in Table 12 below.
[0112] Table 12: CT values of HPV samples extracted with different formulas
[0113]
[0114] From the results in Table 12 above, it can be seen that the best effect is formula 1, which is better than the reagents of other formulas and the control magnetic bead reagent. The entire release time is completed within 4 minutes, and there is no obvious inhibition on the downstream PCR detection.
[0115] For relevant results, please refer to the attached Figure 3 shown.
[0116] Example 4: Effect of different concentrations of SDS on release results;
[0117] 1) Prepare a batch of reagents according to the formula shown in Table 13 for standby use.
[0118] Table 13: Composition of different release agent components used
[0119]
[0120] 2) The experimental process is as follows: The extraction reagent uses the "Nucleic Acid Release Kit" produced by Dexia. The detection kit uses the Dexia Biotech COVID-19 Nucleic Acid Detection Kit. The sample uses the purchased Bondeson COVID-19 corporate reference product and is mixed with the negative oral sample in proportion.
[0121] 3) The extraction process is as follows: For oral swab samples, directly insert the swab into the release agent (3ml tube) or insert the swab head into the preservation solution, add the preservation solution to the release agent (200μL) in a 1:1 ratio, manually shake the release agent after adding the sample left and right 15 times, and let it stand at room temperature for 2 minutes; add it to the PCR reaction reagent for amplification;
[0122] 4) After the extraction of reagents is completed, detection and comparison are performed. The specific detection reaction system is shown in Table 14 below;
[0123] Table 14: PCR reaction system
[0124]
[0125] Amplification Procedure:
[0126]
[0127] The reaction solution was divided into 8 tubes according to the reaction system, and then the extracted nucleic acid was added. The lid was closed, centrifuged instantly, the bubbles were removed, and the PCR was performed on the machine. The CT values of the novel coronavirus (COVID-19) samples extracted with different formulas were amplified as shown in Table 15 below.
[0128] Table 15: CT values of novel coronavirus (COVID-19) samples extracted with different formulas
[0129]
[0130] From the results in Table 15 above, it can be seen that when no SDS is added or when the SDS concentration exceeds 1.0%, the amplification CT value is delayed accordingly, and the release effect is best when the concentration is 0.05%-1%, and there is no obvious inhibition on the downstream PCR detection. The more preferred effect is 0.1%-0.5%.
[0131] Example 5: Effect of different concentrations of guanidine thiocyanate on release results
[0132] 1) Prepare a batch of reagents according to the formula shown in Table 16 for use.
[0133] Table 16: Composition of different release agent components used
[0134]
[0135]
[0136] 2) The experimental process is as follows: The extraction reagent uses the "Nucleic Acid Release Kit" produced by Dexia. The detection kit uses the Dexia Biotech COVID-19 Nucleic Acid Detection Kit. The sample uses the purchased Bondeson COVID-19 corporate reference product and is mixed with the negative oral sample in proportion.
[0137] 3) The extraction process is as follows: For oral swab samples, directly insert the swab into the release agent (3ml tube) or insert the swab head into the preservation solution, add the preservation solution to the release agent (200μL) in a 1:1 ratio, manually shake the release agent after adding the sample left and right 15 times, and let it stand at room temperature for 2 minutes; add it to the PCR reaction reagent for amplification;
[0138] 4) After the extraction of reagents is completed, detection and comparison are performed. The specific detection reaction system is shown in Table 17 below;
[0139] Table 17: PCR reaction system
[0140]
[0141] Amplification Procedure:
[0142]
[0143]
[0144] The reaction solution was divided into 8 tubes according to the reaction system, and then the extracted nucleic acid was added. The lid was closed, centrifuged instantly, the bubbles were removed, and the PCR was performed on the machine. The CT values of the novel coronavirus (COVID-19) samples extracted with different formulas were amplified as shown in Table 18 below.
[0145] Table 18: CT values of novel coronavirus (COVID-19) samples extracted with different formulas
[0146]
[0147] It can be seen from the results in Table 18 above that when no guanidine isothiocyanate is added or when guanidine isothiocyanate is added at a concentration exceeding 50 mM, the amplification CT value is delayed accordingly. The release effect is best when the concentration is 10 mM-50 mM, and there is no obvious inhibition on downstream PCR detection. The more preferred effect is 20 mM-40 mM.
[0148] Example 6: Effect of different concentrations of Tris-HCl on release results
[0149] 1) Prepare a batch of reagents according to the formula shown in Table 19 for use.
[0150] Table 19: Composition of different release agent components used
[0151]
[0152]
[0153] 2) The experimental process is as follows: The extraction reagent uses the "Nucleic Acid Release Kit" produced by Dexia. The detection kit uses the Dexia Biotech COVID-19 Nucleic Acid Detection Kit. The sample uses the purchased Bondeson COVID-19 corporate reference product and is mixed with the negative oral sample in proportion.
[0154] 3) The extraction process is as follows: For oral swab samples, directly insert the swab into the release agent (3ml tube) or insert the swab head into the preservation solution, add the preservation solution to the release agent (200μL) in a 1:1 ratio, manually shake the release agent after adding the sample left and right 15 times, and let it stand at room temperature for 2 minutes; add it to the PCR reaction reagent for amplification;
[0155] 4) After the extraction of reagents is completed, detection and comparison are performed. The specific detection reaction system is shown in Table 20 below;
[0156] Table 20: PCR reaction system
[0157]
[0158] Amplification Procedure:
[0159]
[0160] The reaction solution was divided into 8 tubes according to the reaction system, and then the extracted nucleic acid was added. The lid was closed, centrifuged instantly, the bubbles were removed, and the PCR was performed on the machine. The CT values of the novel coronavirus (COVID-19) samples extracted with different formulas were amplified as shown in Table 21 below.
[0161] Table 21: CT values of novel coronavirus (COVID-19) samples extracted with different formulas
[0162]
[0163] From the results in Table 21 above, it can be seen that without adding Tris-HCl, the amplification CT value is delayed accordingly. When the concentration is above 50mM, the amplification is normal, the release effect is the best, and there is no obvious inhibition on the downstream PCR detection. Considering the economic cost and amplification effect, the more preferred effect is 100mM-250mM.
[0164] Example 7: Effect of different EDTA concentrations on release results
[0165] 1) Prepare a batch of reagents according to the formula shown in Table 22 for use.
[0166] Table 22: Composition of different release agent components used
[0167]
[0168]
[0169] 2) The experimental process is as follows: The extraction reagent uses the "Nucleic Acid Release Kit" produced by Dexia. The detection kit uses the Dexia Biotech COVID-19 Nucleic Acid Detection Kit. The sample uses the purchased Bondeson COVID-19 corporate reference product and is mixed with the negative oral sample in proportion.
[0170] 3) The extraction process is as follows: For oral swab samples, directly insert the swab into the release agent (3ml tube) or insert the swab head into the preservation solution, add the preservation solution to the release agent (200μL) in a 1:1 ratio, manually shake the release agent after adding the sample left and right 15 times, and let it stand at room temperature for 2 minutes; add it to the PCR reaction reagent for amplification;
[0171] 4) After the extraction of reagents is completed, detection and comparison are performed. The specific detection reaction system is shown in Table 23 below;
[0172] Table 23: PCR reaction system
[0173]
[0174] Amplification Procedure:
[0175]
[0176] The reaction solution was divided into 8 tubes according to the reaction system, and then the extracted nucleic acid was added, the lid was closed, centrifuged instantly, the bubbles were removed, and the PCR was performed. The CT values of the amplified COVID-19 samples extracted with different formulas are shown in Table 24 below.
[0177] Table 24: CT values of novel coronavirus (COVID-19) samples extracted with different formulas
[0178]
[0179] It can be seen from the results in Table 24 above that when no EDTA is added or the added amount exceeds 5mM, the amplification CT value is delayed accordingly. When the concentration is in the range of 1-5mM, the amplification is normal, the release effect is the best, and there is no obvious inhibition on downstream PCR detection. The more preferred effect is 1mM-3mM.
[0180] Example 8: Effect of different concentrations of Tween 20 on release results
[0181] 1) Prepare a batch of reagents according to the formula shown in Table 25 for use.
[0182] Table 25: Composition of different release agent components used
[0183]
[0184]
[0185] 2) The experimental process is as follows: The extraction reagent uses the "Nucleic Acid Release Kit" produced by Dexia. The detection kit uses the Dexia Biotech COVID-19 Nucleic Acid Detection Kit. The sample uses the purchased Bondeson COVID-19 corporate reference product and is mixed with the negative oral sample in proportion.
[0186] 3) The extraction process is as follows: For oral swab samples, directly insert the swab into the release agent (3ml tube) or insert the swab head into the preservation solution, add the preservation solution to the release agent (200μL) in a 1:1 ratio, manually shake the release agent after adding the sample left and right 15 times, and let it stand at room temperature for 2 minutes; add it to the PCR reaction reagent for amplification;
[0187] 4) After the extraction of reagents is completed, detection and comparison are performed. The specific detection reaction system is shown in Table 26 below;
[0188] Table 26: PCR reaction system
[0189]
[0190] Amplification Procedure:
[0191]
[0192] The reaction solution was divided into 8 tubes according to the reaction system, and then the extracted nucleic acid was added. The lid was closed, centrifuged instantly, the bubbles were removed, and the PCR was performed on the machine. The CT values of the novel coronavirus (COVID-19) samples extracted with different formulas were amplified as shown in Table 27 below.
[0193] Table 27: CT values of novel coronavirus (COVID-19) samples extracted with different formulas
[0194]
[0195] It can be seen from the results in Table 27 above that when Tween 20 is not added and the addition amount exceeds 10%, the amplification CT value is significantly delayed accordingly. When the concentration is in the range of 0.1-10%, the amplification is normal, the release effect is good, and there is no obvious inhibition on downstream PCR detection. The more preferred effect is 0.5%-1%.
[0196] Example 9: Effect of different concentrations of ammonium sulfate on release results
[0197] 1) Prepare a batch of reagents according to the formula shown in Table 28 for use.
[0198] Table 28: Composition of different release agent components used
[0199]
[0200]
[0201] 2) The experimental process is as follows: The extraction reagent uses the "Nucleic Acid Release Kit" produced by Dexia. The detection kit uses the Dexia Biotech COVID-19 Nucleic Acid Detection Kit. The sample uses the purchased Bondeson COVID-19 corporate reference product and is mixed with the negative oral sample in proportion.
[0202] 3) The extraction process is as follows: For oral swab samples, directly insert the swab into the release agent (3ml tube) or insert the swab head into the preservation solution, add the preservation solution to the release agent (200μL) in a 1:1 ratio, manually shake the release agent after adding the sample left and right 15 times, and let it stand at room temperature for 2 minutes; add it to the PCR reaction reagent for amplification;
[0203] 4) After the extraction of reagents is completed, detection and comparison are performed. The specific detection reaction system is shown in Table 29 below;
[0204] Table 29: PCR reaction system
[0205]
[0206] Amplification Procedure:
[0207]
[0208] The reaction solution was divided into 8 tubes according to the reaction system, and then the extracted nucleic acid was added. The lid was closed, centrifuged instantly, the bubbles were removed, and the PCR was performed on the machine. The CT values of the novel coronavirus (COVID-19) samples extracted with different formulas were amplified as shown in Table 30 below.
[0209] Table 30: CT values of novel coronavirus (COVID-19) samples extracted with different formulas
[0210]
[0211] It can be seen from the results in Table 30 above that when no ammonium sulfate is added or the addition amount exceeds 400mM, the amplification CT value is significantly delayed accordingly. When the concentration is in the range of 20mM-200mM, the amplification is normal, the release effect is good, and there is no obvious inhibition on downstream PCR detection. The more preferred effect is 100mM-150mM.
[0212] Example 10: Effect of different release times on release results
[0213] 1) Formula 47 of Example 9 was used to release the oral samples mixed with the new coronavirus (COVID-19) at different times. The experimental process was as follows: The extraction reagent used was the "Nucleic Acid Release Kit" produced by Dexia. The detection kit used was the Dexia Bio New Coronavirus (COVID-19) Nucleic Acid Detection Kit. The sample was purchased from Bondeson New Coronavirus (COVID-19) Enterprise Reference Products and mixed into the negative oral sample in proportion.
[0214] 2) The extraction process is as follows: add the preservation solution to the release agent (200 μL) at a ratio of 1:1, manually shake the release agent left and right 15 times, let it stand at room temperature for 1-10 minutes, and then add it to the PCR reaction reagent for amplification;
[0215] 3) After the extraction of reagents is completed, detection and comparison are performed. The specific detection reaction system is shown in Table 31 below;
[0216] Table 31: PCR reaction system
[0217]
[0218] Amplification Procedure:
[0219]
[0220] The reaction solution was divided into 8 tubes according to the reaction system, and then the extracted nucleic acid was added. The lid was closed, centrifuged instantly, the bubbles were removed, and the PCR was performed on the machine. The CT values of the novel coronavirus (COVID-19) samples extracted at different release times were amplified as shown in Table 32 below.
[0221] Table 32: Amplified CT values of novel coronavirus (COVID-19) samples extracted at different release times
[0222]
[0223] It can be seen from the results in Table 32 above that the release time of the release agent is 1-10 min, the amplification is normal, the release effect is good, and there is no obvious inhibition on the downstream PCR detection. Considering the time cost, the release time of 1-3 min meets the expected requirements.
[0224] Embodiment 11
[0225] Effects of different ratios of sample to release agent on release results
[0226] 1) Formula 47 was used to conduct a proportional experiment of different sample volumes on oral samples mixed with the new coronavirus (COVID-19). The experimental process was as follows: The extraction reagent used was the "Nucleic Acid Releaser Kit" produced by Dexia. The detection kit used was the Dexia Bio New Coronavirus (COVID-19) Nucleic Acid Detection Kit. The sample was purchased from Bondeson New Coronavirus (COVID-19) Enterprise Reference Products and mixed into the negative oral sample in proportion.
[0227] 2) The extraction process is as follows: add the preservation solution to the release agent (100 μL) at a ratio of 1: (0.5-15), manually shake the release agent left and right 15 times, let it stand at room temperature for 2 minutes, and then add it to the PCR reaction reagent for amplification; the specific detection reaction system is shown in Table 33 below;
[0228] Table 33: PCR reaction system
[0229]
[0230] Amplification Procedure:
[0231]
[0232] The reaction solution was divided into 8 tubes according to the reaction system, and then the extracted nucleic acid was added. The lid was closed, centrifuged instantly, the bubbles were removed, and the PCR was performed on the machine. The amplification results of the novel coronavirus (COVID-19) samples extracted with different ratios of sample and release agent are shown in Table 34 below.
[0233] Table 34: Amplification results of novel coronavirus (COVID-19) samples extracted with different ratios of sample and release agent
[0234]
[0235]
[0236] It can be seen from the results in Table 34 above that for oral samples of the new coronavirus (COVID-19), the best effect is achieved when the ratio of sample to release agent is 1:(1-5). A ratio higher or lower than this will have a certain impact.
[0237] Example 12: Effect of different sample amounts after release on amplification results of freeze-dried reagents
[0238] 1) Formula 47 shown in Example 9 was used to evaluate the addition of different amplified samples to the oral samples mixed with the new coronavirus (COVID-19). The experimental process was as follows: The extraction reagent used was the "Nucleic Acid Releaser Kit" produced by Dexia. The detection kit used was the Dexia Bio New Coronavirus (COVID-19) Nucleic Acid Detection Kit. The sample was purchased from Bondeson New Coronavirus (COVID-19) Enterprise Reference Products and mixed into the negative oral sample in proportion.
[0239] 2) The extraction process is as follows: add the preservation solution to the release agent (200 μL) at a ratio of 1:1, manually shake the release agent left and right 15 times, let it stand at room temperature for 2 minutes, and then add it to the PCR reaction reagent according to the ratio in Table 35 for amplification;
[0240] Table 35: Sample volumes added to PCR reagents
[0241]
[0242] Amplification Procedure:
[0243]
[0244] The reaction solution was divided into 8 tubes according to the reaction system, and then the extracted nucleic acid was added. The lid was closed, centrifuged instantly, the bubbles were removed, and the PCR was performed on the machine. The amplification results for the different volumes of sample added to the PCR reagent are shown in Table 36 below.
[0245] Table 36: Amplification results of adding different volumes of sample to PCR reagent
[0246]
[0247]
[0248] It can be seen from the results in Table 36 above that for oral samples of the new coronavirus (COVID-19), as the sample size increases, PCR amplification does not show inhibition, but the peak time is advanced, proving that the reagent of the present invention does not significantly inhibit the subsequent addition of the full template amount of the freeze-dried reagent.
[0249] Example 13: Effect of release agent on sample preservation
[0250] 1) Formula 47 shown in Example 9 was used to evaluate the effect of oral samples, blood samples and HPV samples mixed with the new coronavirus (COVID-19) as a preservation solution. The experimental process was as follows: The extraction reagent used was the "Nucleic Acid Releaser Kit" produced by Dexia Company. The detection kit used was the Dexia Bio New Coronavirus (COVID-19) Nucleic Acid Detection Kit / HBV Nucleic Acid Detection Kit / HPV Nucleic Acid Detection Kit. The samples used the purchased Bondeson New Coronavirus (COVID-19) corporate reference products, HBV nucleic acid samples and Jingliang HPV nucleic acid samples.
[0251] 2) The extraction process is as follows: add the preservation solution to the release agent (200 μL) at a ratio of 1:1, store at room temperature, and test according to Table 37 below;
[0252] Table 37: Sample volumes added to PCR reagents
[0253]
[0254] The amplification program is shown in Table 38 below:
[0255] Table 38: Amplification procedures for three reagents
[0256]
[0257] The reaction solution was divided into 8 tubes according to the reaction system, and then the extracted nucleic acid was added. The lid was closed, centrifuged instantly, the bubbles were removed, and the PCR was performed on the machine. The amplification results for different volumes of sample added to the PCR reagent are shown in Table 39 below.
[0258] Table 39: Amplification results of adding different volumes of sample to PCR reagent
[0259]
[0260] It can be seen from the results in Table 39 above that: for the release agent as the sample preservation liquid, there was no significant difference in the new coronavirus (COVID-19), HBV virus and HPV virus within 48 hours, and PCR amplification did not show inhibition. On the contrary, the peak time was advanced, proving that the reagent of the present invention did not significantly inhibit the subsequent addition of the full template amount of the freeze-dried reagent.
[0261] Furthermore, through the above 13 embodiments, it can be summarized that the nucleic acid releaser suitable for rapid release of multiple samples according to the embodiments of the present invention includes guanidine thiocyanate with a concentration of 10mM-50mM, ammonium sulfate with a concentration of 20mM-200mM, a metal ion chelator with a concentration of 1mM-5mM, a buffer with a concentration of 50mM-500mM, a non-ionic detergent with a volume percentage of 0.1%-10%, an anion active agent with a volume percentage of 0.05%-1%, and a PCR enhancer with a volume percentage of 0.05%-5%, and the concentration of the guanidine thiocyanate is preferably 20mM-40mM, the concentration of the ammonium sulfate is preferably 100mM-150mM, the metal ion chelator is ethylenediaminetetraacetic acid (EDTA), and its concentration is preferably 1mM-3mM, and the buffer is T The present invention is characterized in that the present invention comprises a ris-HCl buffer, the concentration of which is preferably 100mM-250mM; the non-ionic detergent comprises TritonX-100, Tween-20 and ethylphenyl polyethylene glycol (NP-40), the volume percentage of which is preferably 0.1%-5%, more preferably 0.5%-1%, the anionic active agent comprises sodium dodecyl sulfate (SDS) and sodium lauroyl sarcosinate (SLS), the volume percentage of which is preferably 0.1%-0.5%, the PCR enhancer preferably comprises trehalose, betaine and formamide; the pH value of the nucleic acid releaser is preferably 7.5-8.5, the volume ratio of the nucleic acid releaser to the nucleic acid sample is preferably 1:(1-10), and the operating temperature of the nucleic acid releaser is preferably 10°C-30°C. The present invention obviously has the following technical effects:
[0262] First, the nucleic acid releaser of the present invention has a protein structure that can quickly crack cells, viruses, etc., and can complete sample release within 1-3 minutes at room temperature, greatly shortening the sample extraction time and saving a lot of time for subsequent rapid testing.
[0263] Second, the nucleic acid releaser of the present invention can be used as a sample preservation liquid to provide protection for bacteria and viruses in the oral cavity, blood, and cervical exfoliated cells, and prevent degradation by DNase and RNase enzymes. There is no significant degradation of nucleic acid samples stored and transported for more than 2 days at room temperature.
[0264] Thirdly, the present invention contains various active agents and strong protein denaturants, which can quickly inactivate viruses and other pathogenic microorganisms in samples and has high safety.
[0265] Fourthly, the nucleic acid release method of the present invention is compatible with multiple samples and can quickly release nucleic acids from serum, plasma, oral swabs, and cervical exfoliated cell samples. The released nucleic acids can be used for downstream experiments such as PCR, cloning, sequence analysis, and molecular hybridization.
[0266] Fifthly, the nucleic acid releaser of the present invention can be used as a resolubilizing agent in a freeze-dried reagent without adding an additional resolubilizing agent or water, and the addition of the whole sample has no significant inhibitory effect on the freeze-dried reagent.
[0267] Other embodiments and the like are not described here by way of example.
[0268] Furthermore, the nucleic acid release agent and nucleic acid release method suitable for rapid release of multiple samples provided by the present application are indeed extremely practical and have excellent use effects, which makes the present application bound to have great market promotion value, and the present application is bound to be very popular and will be effectively popularized.
[0269] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0270] The above description is only a preferred embodiment of the present invention, and does not limit the patent scope of the present invention. All equivalent structural changes made by using the contents of the present invention specification and drawings under the inventive concept of the present invention, or directly / indirectly applied in other related technical fields are included in the patent protection scope of the present invention.
Claims
1. A nucleic acid release agent suitable for rapid release of multiple samples, characterized in that: It includes guanidine thiocyanate at a concentration of 10mM-50mM, ammonium sulfate at a concentration of 20mM-200mM, a metal ion chelator at a concentration of 1mM-5mM, a buffer solution at a concentration of 50mM-500mM, a non-ionic detergent with a volume percentage of 0.1%-10%, an anionic active agent with a volume percentage of 0.05%-1% and a PCR enhancer with a volume percentage of 0.05%-5%.
2. The nucleic acid releasing agent suitable for rapid release of multiple samples according to claim 1, characterized in that: The concentration of the guanidine isothiocyanate is 20 mM-40 mM.
3. The nucleic acid releasing agent suitable for rapid release of multiple samples according to claim 1, characterized in that: The concentration of the ammonium sulfate is 50 mM-150 mM.
4. The nucleic acid releasing agent suitable for rapid release of multiple samples according to claim 1, characterized in that: The metal ion chelating agent is ethylenediaminetetraacetic acid (EDTA) with a concentration of 1 mM-3 mM.
5. The nucleic acid releasing agent suitable for rapid release of multiple samples according to claim 1, characterized in that: The buffer is Tris-HCl buffer, and its concentration is 100mM-250mM.
6. The nucleic acid releasing agent suitable for rapid release of multiple samples according to claim 1, characterized in that: The non-ionic detergent comprises Triton X-100, Tween 20 and ethylphenyl polyethylene glycol (NP-40), and the volume percentage thereof is 0.1%-5%.
7. The nucleic acid releasing agent suitable for rapid release of multiple samples according to claim 1, characterized in that: The anionic active agent comprises sodium dodecyl sulfate (SDS) and sodium lauroyl sarcosinate (SLS), and the volume percentage thereof is 0.1%-0.5%.
8. The nucleic acid releasing agent and nucleic acid releasing method suitable for rapid release of multiple samples according to claim 1, characterized in that: The PCR enhancer comprises one or more of trehalose, betaine, bovine serum albumin, glycine, gelatin, glycine and formamide, and the volume percentage thereof is 0.1%-1%.
9. A method for releasing nucleic acid, characterized in that: The nucleic acid releaser according to any one of claims 1 to 8 is used for PCR detection of nucleic acid, wherein the pH value of the nucleic acid releaser is 7.5-8.
5.
10. The method for releasing nucleic acid according to claim 9, characterized in that: The volume ratio of the nucleic acid releaser to the nucleic acid sample is 1:(1-10), the operating temperature of the nucleic acid releaser is 10°C-30°C, and the release time of the nucleic acid releaser is 1min-3min.
Citation Information
Cited By
Extraction-free rapid nucleic acid releasing agent and application thereof
CN119614674A
